{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Publication Policy', 'The results of this study in aggregate may be published or presented at scientific meetings.', 'If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the', 'Sponsor before submission. This allows the Sponsor to protect proprietary information and', 'to provide comments. No individual site related study results will be allowed to be', 'presented.', 'The Sponsor will comply with the requirements for publication of study results. In', 'accordance with standard editorial and ethical practice, the Sponsor will generally support', 'publication of multicenter studies only in their entirety and not as individual study center', 'data. In this case, a Coordinating Investigator will be designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with International', 'Committee of Medical Journal Editors authorship requirements.', '60']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Appendix 3', 'Clinical Laboratory Tests', 'Subjects must be fasting (at least 8 hours) for Visit 1 (Screening) and, if possible, for Visit 6 (EOS);', 'however, if a subject arrives at the clinic for Visit 6 (EOS) without fasting for at least 8 hours,', 'laboratory specimens may be collected as non-fasting, at the discretion of the Investigator, and', 'documented as such on the laboratory requisition form.', 'The tests detailed in Table 7 will be performed by the central laboratory.', 'Local laboratory results are only required if the central laboratory results are not available', 'in time for either study treatment administration and/or response evaluation. If a local', 'sample is required, it is important that the sample for central analysis is obtained at the', 'same time. Additionally, if the local laboratory results are used to make either a study', 'treatment decision or response evaluation, the results must be entered into the eCRF.', 'Protocol-specific requirements for inclusion or exclusion of subjects are detailed in', 'Section 5.0.', 'Additional tests may be performed at any time during the study as determined necessary', 'by the Investigator or required by local regulations.', 'Table 7', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Assessments', 'Parameters', 'Hematology', 'Platelet Count', 'RBC Indices:', 'White Blood Cell Count', 'Mean Corpuscular Volume', 'with Differential:', 'Red Blood Cell (RBC) Count', '(MCV)', 'Neutrophils', 'Hemoglobin', 'Mean Corpuscular Hemoglobin', 'Lymphocytes', 'Hematocrit', '(MCH)', 'Monocytes', '% Reticulocytes', 'Eosinophils', 'Basophils', 'Clinical', 'Blood Urea', 'Potassium', 'Aspartate Aminotransferase', 'Total and', 'Chemistry', 'Nitrogen', '(AST)/Serum Glutamic-Oxaloacetio', 'Direct Bilirubin', 'Transaminase (SGOT)', 'Creatinine', 'Sodium', 'Alanine Aminotransferase', 'Total Protein', '(ALT)/Serum Glutamic-Pyruvic', 'Transaminase (SGPT)', 'Glucose (Fasting)', 'Calcium', 'Alkaline Phosphatase', 'Routine', 'Specific Gravity', 'Urinalysis', 'pH, Glucose, Protein, Blood, Ketones, (Bilirubin, Urobilinogen, Nitrite, Leukocyte', 'Esterase) by Dipstick', 'Microscopic Examination (if Blood or Protein Is Abnormal)', 'Other Screening', 'Urine Human Chorionic Gonadotropin (hCG) Pregnancy Test (as Needed for Women of', 'Tests', 'Childbearing Potential)', 'Serology (human immunodeficiency virus [HIV] Antibody)', '61']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Laboratory', 'Assessments', 'Parameters', 'All study-required laboratory assessments will be performed by a central laboratory, with', 'the exception of urine pregnancy testing.', 'The results of each test must be entered into the (e)CRF.', '62']\n\n###\n\n", "completion": "END"}